Literature DB >> 18421044

Assessing the measure of a new drug: is survival the only thing that matters?

Daniel J Sargent, Daniel F Hayes.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18421044     DOI： 10.1200/JCO.2007.14.8064

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  27 in total

1.  Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Authors:  Joseph A Sparano; Eduard Vrdoljak; Oliver Rixe; Binghe Xu; Alexey Manikhas; Carlos Medina; Susanne Crocamo Ventilari Da Costa; Jungsil Ro; Gonzalo Rubio; Monica Rondinon; Gumersindo Perez Manga; Ronald Peck; Valerie Poulart; Pierfranco Conte
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

Review 2.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

3.  Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors:  Boris Freidlin; Richard F Little; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

Review 4.  The value of progression-free survival to patients with advanced-stage cancer.

Authors:  Lesley J Fallowfield; Anne Fleissig
Journal:  Nat Rev Clin Oncol       Date:  2011-10-18       Impact factor: 66.675

5.  [Health-related quality of life].

Authors:  Luis Lizán Tudela
Journal:  Aten Primaria       Date:  2009-05-15       Impact factor: 1.137

Review 6.  Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

Authors:  Edward L Korn; Boris Freidlin; Jeffrey S Abrams
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 7.  Rethinking the metastatic cascade as a therapeutic target.

Authors:  Lida A Mina; George W Sledge
Journal:  Nat Rev Clin Oncol       Date:  2011-04-19       Impact factor: 66.675

Review 8.  Methods and challenges in quantitative imaging biomarker development.

Authors:  Richard G Abramson; Kirsteen R Burton; John-Paul J Yu; Ernest M Scalzetti; Thomas E Yankeelov; Andrew B Rosenkrantz; Mishal Mendiratta-Lala; Brian J Bartholmai; Dhakshinamoorthy Ganeshan; Leon Lenchik; Rathan M Subramaniam
Journal:  Acad Radiol       Date:  2015-01       Impact factor: 3.173

9.  [Chemotherapy of colorectal cancer].

Authors:  A Reinacher-Schick; M Pohl; W Schmiegel
Journal:  Internist (Berl)       Date:  2009-11       Impact factor: 0.743

10.  Progression-free survival as a surrogate endpoint in advanced breast cancer.

Authors:  Rebecca A Miksad; Vera Zietemann; Raffaella Gothe; Ruth Schwarzer; Annette Conrads-Frank; Petra Schnell-Inderst; Björn Stollenwerk; Uwe Siebert
Journal:  Int J Technol Assess Health Care       Date:  2008       Impact factor: 2.188
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.